Fundraising Fox
Casdin Capital
Crossover fundNew York · Seed–Series C · 38 people tracked
Also known as CASDIN CAPITAL, LLC
Find your way into Casdin Capital
1,741 people in our graph share verified history with the Casdin Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Casdin Capital invests across the life sciences sector, spanning healthcare, biotechnology, synthetic biology, and technology. The firm believes great medicines make great investments and targets companies leveraging the growing ability to read and manipulate molecular information. Its approach centers on partnering with companies and building positions to create value over time, emphasizing patience, persistence, and strong relationships. The firm's guiding formula is to aim at large markets, back great ideas and teams, stay focused, and avoid hubris. With decades of experience, Casdin positions itself as one of the few expert investors in the field.
Source: firm website, verified Sep 29, 2026.
Team · 38 people
from the firm's website
Founder mafia
2 people who came through Casdin Capital went on to found or lead other companies.
What they invest in
from 59 of 68 portfolio companiesBiotech ×47Healthtech ×27AI & Machine Learning ×23Deep Tech ×21Medical Devices ×18Digital Health ×11Data & Infrastructure ×4SaaS ×4
HQs:United States×48United Kingdom×2Canada×1Japan×1Netherlands×1
Investments · 68 tracked
founders shown can be your intro pathBy year:2026 · 62025 · 32024 · 22023 · 22022 · 62021 · 212020 · 72019 · 42018 · 52017 · 12016 · 158 dated
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch.
AI & Machine LearningBiotechDeep TechPortland, US
Sean McClain(Executive Officer)inPhil Barish(Executive Officer)inZachariah Jonasson(Chief Financial Officer and Chief Business Officer)Shelby Walker(Chief Legal Officer)inRansi Somaratne(Chief Medical Officer)Andreas Busch(Chief Innovation Officer)in
Board seatEli Casdin· per SEC Form D
Co-investorsConvergent VenturesDas & Co.IKJ CapitalOregon Venture FundPhoenix Venture PartnersTachyon Ventures+4 more
Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer.
AI & Machine LearningBiotechHealthtechMedical DevicesPhiladelphia, US
Osvaldo Flores, Ph.D.(Executive Officer, Director)Douglas Carr(Executive Officer)inBrent Pfeiffenberger(President and Chief Executive Officer)inGregory Russotti(Chief Technology and Manufacturing Officer)Chad Cowan(Chief Scientific Officer)in
BoardToshikazu Ban(Director)
Board seatEli Casdin· per SEC Form D
Co-investorsLifeSci Venture PartnersRA CapitalVersant Ventures
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Executive Officer, Director)inDavid Schaffer(Director)inTheresa Janke(Executive Officer)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityChiesi VenturesPappas CapitalPfizer Venture Investments+6 more
908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications.
Deep TechDefense TechHardwareMedical DevicesBoston, US
Kevin J. Knopp, PhD(CEO & Co-founder)Christopher Brown(Executive Officer)inKevin Knopp(Executive Officer, Director)inJoseph Griffith IV(Executive Officer)
BoardKevin Hrusovsky(Director)Corey Steffek(Director)
Co-investorsARCH Venture PartnersRazor's Edge VenturesUTECAramco VenturesARK Investment ManagementBlackRock+3 more
Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.
BiotechHealthtech
Carmine Stengone(President and Chief Executive Officer)inCarmine N. Stengone(President, Chief Executive Officer and Director)inPeter T. Slover(Chief Financial Officer)inDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in
Co-investorsHadean VenturesRed Tree VentureSamsara BioCapitalFranklin TempletonJJDCSectoral Asset Management+1 more
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.+9 more
Neurogene develops gene therapy treatments for rare neurological diseases.
BiotechDeep TechDigital HealthLongevityMedical DevicesNew York, US
Rachel McMinn(Founder and Chief Executive Officer)inRachel McMinn, Ph.D.(Founder and Chief Executive Officer)
BoardCory Freedland(Director)inStephen Biggar(Director)
Co-investorsEcoR1 CapitalSamsara BioCapitalREDMILERTW Investments L.P.William Blair
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Co-founder and Head of Platform)inDavid Liu(Co-founder)inAllan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in
Co-investorsARCH Venture PartnersGV (Google Ventures)Newpath PartnersF-Prime CapitalOUP (Osage University Partners)Samsara BioCapital+1 more
Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission.
BiotechDeep TechHealthtechLeiden, NL
Koenraad Wiedhaup(Founder & Chief Executive Officer)inRonald Brus(Founder & Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)inDinko Valerio(Founder and Chair of the Supervisory Board)inJintanat Ananworanich(Chief Medical Officer)inClarissa Koch(Chief Scientific Officer)in
Co-investorsClavystBioF-Prime CapitalGV (Google Ventures)Bluebird VenturesEuropean Innovation Council FundEuropean Investment Bank+6 more
C2i Genomics develops a whole-genome sequencing platform that uses AI algorithms to build patient-specific cancer signatures for detecting minimal residual disease (MRD) and monitoring cancer.
AI & Machine LearningBiotechDigital HealthHealthtechNew York, US
Asaf Zviran(Founder)inEzra Sofer(Executive Officer, Director)
BoardAlex Parker(Director)Shaun Rodriguez(Director)in
Board seatEli Casdin· per SEC Form D
Co-investorsiGlobe PartnersLionBirdNat TurnerNFXSection 32
Genomatica (Geno) develops biotechnology processes to produce bio-based chemicals and materials—such as 1,4-butanediol (BDO), butylene glycol for cosmetics, and plant-based nylon—as alternatives to fossil-fuel-derived inputs.
BiotechCircular EconomyCleantechClimate TechNew MaterialsSan Diego, US
Christophe Schilling(Co-founder (former CEO))inBernhard Palsson(Co-founder)Carlos A. Cabrera(Executive Chairman)inJohn G. Gugel(Chief Executive Officer)inTom McDonald(SVP, Finance & Chief Financial Officer)inNelson Barton(SVP, Research and Development)in
Board seatEli Casdin· per SEC Form D · $119.1M raise · filed Aug 2021
Co-investorsThule InvestmentsVantagePoint Capital PartnersDraper Fisher Jurvetson (DFJ)Mohr Davidow VenturesNovo Holdings
SomaLogic develops proteomics tools that help researchers measure protein function and study human biology across a range of scientific applications.
BiotechDeep TechHealthtechBoulder, US
Larry Gold(Director)inLarry Gold PhD(Founder)inDaniel Muehl(Executive Officer)Byron Hewett(Executive Officer, Director)in
BoardCharles Lillis(Director)Youichi Yabuuchi(Director)
Board seatEli Casdin· per SEC Form D
Co-investorsForesite CapitalKhosla VenturesMagnetar CapitalReimagined VenturesSoleus CapitalT. Rowe Price
23andMe operates a research platform that collects genetic data from millions of users to advance genomic research and health discovery.
BiotechDigital HealthDirect to ConsumerHealthtechLongevityMountain View, US
Anne Wojcicki(CEO and Founder)inLinda Avey(Co-founder)Paul Cheung(Co-founder)Andrew Page(Executive Officer, Director)Kathy Hibbs(Executive Officer)in
BoardEsther Dyson(Director)in
Co-investorsAdam NashAllied Venture PartnersCivilization Ventures Management, LlcEQUIAMFirebolt Ventures Management Company, LlcG Squared+16 more
Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.
South San Francisco, US
Co-investorsBain Capital Life SciencesFrazier Life SciencesLongitude CapitalBlackRockFranklin TempletonFrazier Healthcare Partners+5 more
Apella provides real-time operating room monitoring and predictive analytics through computer vision and AI integration with EHR systems, helping surgical teams detect delays, optimize scheduling, and improve OR efficiency.
AI & Machine LearningDigital HealthHealthtech
Co-investorsK2 HealthVenturesLayout VenturesOPAMP CAPITALTwine VenturesHighlandXOperator Partners+2 more
Asimov collects real-world human activity data at scale from diverse environments to create annotated datasets for training robotics AI models.
Advanced ManufacturingAI & Machine LearningData & InfrastructureRoboticsSan Francisco, US
Lyem Ningthou(Founder)in
Co-investorsY CombinatorAME Cloud VenturesAndreessen Horowitz
Asimov develops a computer-aided design platform for genetic engineering, enabling designers to program living cells by applying abstraction, standardization, and modeling to biology.
AI & Machine LearningBiotechDeep TechDeveloper ToolsBoston, US
Chris Voigt(Co-founder)inDoug Densmore(Co-founder)inAlec Nielsen(Co-founder & CEO)inRaja Srinivas(Co-founder)inDouglas Densmore(Co-Founder)in
Co-investorsAndreessen HorowitzDCVC (Data Collective)K5 GlobalKoch Disruptive TechnologiesPillar VCWing+1 more
Beacon Biosignals develops AI-powered EEG analytics technology to improve diagnosis and treatment of neurological, psychiatric, and sleep disorders.
AI & Machine LearningBiotechDigital HealthMedical DevicesBoston, US
Jacob A. Donoghue, M.D., Ph.D.(Executive Officer, Director)Jacob A. Donoghue(Executive Officer, Director, Promoter)inJacob Donoghue(CEO & Co-Founder)inJarrett Revels(CTO & Co-Founder)in
BoardCaitlin Donovan(Director)Pavel Raifeld(Director)
Co-investorsGeneral CatalystAlumni VenturesCatalio Capital Management, LPGV (Google Ventures)Iaso VenturesKicker Ventures+3 more
.png)
Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine.
HealthtechCambridge, US
Tariq Kassum(Executive Officer, Director)inMichael Boretti(Executive Officer)inChristoph Lengauer(Executive Officer, Director)in
Co-investorsCatalio Capital Management, LPFast Track InitiativeGV (Google Ventures)AlexandriaThird Rock Ventures
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)in
Co-investorsAN Venture PartnersARCH Venture PartnersSofinnova VenturesFidelity InvestmentsInvusNYBC Ventures+2 more
BiotechCambridge, US
Chad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)
BoardMartin Murphy(Director)
Co-investorsLifeSci Venture PartnersBain Capital Life SciencesVenrock Healthcare Capital Partners
Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease.
AI & Machine LearningBiotechDeep Tech
Co-investorsBioBritDCVC (Data Collective)DCVC BioTenmileAlexandriaLux Capital
Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases.
AI & Machine LearningBiotechWatertown, US
Eric Kelsic(CEO & Cofounder)inSam Sinai(Vice President, Head of ML & Cofounder)inAdrian Veres(Chief Scientific Officer & Cofounder)inGeorge Church(Scientific Cofounder, SAB)inTomas Bjorklund(Scientific Co-founder, SAB)inAlan Crane(Executive Chairman & Cofounder, Polaris Entrepreneur Partner)in
Co-investorsAndreessen HorowitzCRV (Charles River Ventures)GENERAL INCEPTIONGV (Google Ventures)Lux CapitalObvious Ventures+2 more
EQRx was a Cambridge, MA biopharma that aimed to sell lower-priced novel drugs; it was acquired by Revolution Medicines in 2023.
Co-investorsAndreessen HorowitzArboretum VenturesARCH Venture PartnersGV (Google Ventures)Nextech InvestBain Capital+1 more
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuinAlan Saghetelian
Co-investorsNewpath PartnersCRV (Charles River Ventures)Nextech InvestRaptor GroupSamsara BioCapitalBiotechnology Value Fund+1 more
Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesOakland, US
Martin Reese(Co-Founder, President, and CEO)inMartin Reese, Ph.D.(Co-Founder, President, and CEO)Erwin Frise(Vice President of Technology and Data Science)in
Co-investorsArtis VenturesForesite CapitalMighty Capital
Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.
AI & Machine LearningFuture of WorkHR TechTokyo, JP
Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))
Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalInvusNextech Invest+2 more
Flare is a Shopify app that lets merchants set delivery-date rules by postcode, product, and shipping method so customers only see fulfillable dates at checkout, with automation for cut-off times, order tagging, and 3PL syncing.
E-commerceLogistics & Supply ChainRetail TechSaaSLondon, GB
Daniel Parekh-Hill(CEO)inAlex Hooper(CTO)in
Co-investorsEntrepreneur FirstAgent CapitalBase10 PartnersInovia CapitalInvusNextech Invest+3 more
Flatiron Health combines AI-powered technology and clinical expertise with real-world oncology data to help healthcare providers and life science organizations improve cancer care and research.
AI & Machine LearningData & InfrastructureHealthtechMedical DevicesNew York, US
Nat Turner(Cofounder)inZachary Weinberg(Director, Executive Officer)Nathan Hubbard(Chief Executive Officer)inMichael Bierl(Chief Business Officer)inCal Brouilette(Chief Financial Officer)inAllison Candido(Chief Technology Officer)in
Co-investorsCarnrite VenturesFirst Round CapitalGreat Oaks Venture CapitalGV (Google Ventures)StripesSV Angel+4 more
Formation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesSaaSNew York, US
Ben Liu(CEO & Co-Founder)inLinhao Zhang(Co-Founder)inBenjamine Liu(Founder)in
BoardAlfred Lin(Director)inMichael Moritz(Director)inScott Kupor(Director)in
Co-investorsAndreessen HorowitzSequoia CapitalSam AltmanSection 32Thrive CapitalFelicis Ventures+10 more
BiotechCambridge, US
Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)
BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)
Co-investorsAtlas VentureForesite CapitalDeerfield Management CompanyF-Prime CapitalFidelity InvestmentsInvus
Genome Medical provides telehealth-enabled genetic services, including genetic counseling, genetic testing, and clinical trial matching, with a focus on individuals with rare conditions.
BiotechDigital HealthHealthtech
Mark Sylvester(Chief Financial Officer)inAndrew Warner(Vice President, Product)inMonica Zarb(Vice President, Business Development)inDurand Van Arnem(Vice President, Engineering)inAlan Rope(Medical Director)in
Co-investorsAvestria VenturesCanaan PartnersDreamers VCEcho Health VenturesGV (Google Ventures)Illumina Ventures+8 more
Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.
BiotechDeep TechHealthtechMenlo Park, US
Colin James Bell Harvey(Director)Brian T. Naughton(Director)inMaureen E. Hillenmeyer(Executive Officer, Director)inMaureen Hillenmeyer(CEO & Co-Founder)in
BoardAlex Kolich(Director)
Co-investorsATEL VenturesB3 HoldingNextech InvestSoftBank Vision FundThe Column Group8VC+1 more
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(Founder & CEO)inDuane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in
BoardRobert Nelsen(Director)Vijay Pande(Director)in
Co-investorsAndreessen HorowitzARCH Venture PartnersDeviation CapitalForesite CapitalGV (Google Ventures)HOF Capital+9 more
Boston, US
Jurgen Horn(Executive Officer, Director)
BoardPhilip Austin(Director)in
Co-investorsF-Prime CapitalGV (Google Ventures)Anterra CapitalEight Roads VenturesNovo Holdings
Komodo integrates healthcare data across providers, health systems, care settings, and payers to deliver insights on disease incidence, treatment patterns, and health outcomes.
AI & Machine LearningData & InfrastructureHealthtechSan Francisco, US
Web Sun(Co-Founder/Co-CEO)inArif Nathoo(Co-Founder/Co-CEO)in
Co-investorsAndreessen HorowitzCoatue ManagementFelicis VenturesICONIQMcKesson VenturesNZ Growth Capital Partners+6 more
Lyra provides mental health care services through a network of evidence-based providers, combining clinical expertise with technology to deliver accessible, quality care for employers and health plans.
Digital HealthEnterprise SoftwareHealthtechHR TechMental HealthBurlingame, US
David Ebersman(Co-Founder & Chairman (CEO 2015–2025))inBob Kocher(Co-Founder and Board Member)inDena Bravata(Co-Founder & former Chief Medical Officer)Alethea Varra(Vice President of Clinical Care)inJennifer Schulz(Chief Executive Officer)Elaine Yang(Executive Officer)in
Co-investorsAdditionBreyer CapitalCoatue ManagementDragoneer Investment GroupDurable Capital PartnersFidelity Investments+12 more
Meiogenix develops a proprietary recombination technology that targets meiotic recombination to accelerate genetic gain and variety development in crops.
AgTechBiotechDeep Tech
Ricardo Garcia de Albain
Co-investorsGenoa VenturesKurma PartnersSofinnova Partners
Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.
Co-investorsSofinnova PartnersAlexandriaREDMILE
Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification.
BiotechDeep TechNew MaterialsSan Diego, US
J. William Efcavitch, Ph.D.(Treasurer and Chief Scientific Officer)Michael J. Kamdar(President, Chief Executive Officer and Secretary)
BoardDavid Hwang(Director)Larry Stambaugh(Chairman of the Board of Directors)John Nicols(Director)Todd Peterson(Director)
Co-investors11.2 CapitalDCVC (Data Collective)iSelect FundKeshif VenturesRising TideAlexandria+2 more
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
Biotech
Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in
Co-investorsLifeSci Venture PartnersNextech InvestThird Rock VenturesAlexandriaCreacion VenturesGoldman Sachs+3 more
Multiply Labs builds robotic systems that automate biologics manufacturing for pharmaceutical companies.
Advanced ManufacturingBiotechDeep TechRoboticsSan Francisco, US
Fred Parietti(Co-Founder & CEO)inAlice Melocchi(Co-Founder & CSO)in
BoardShaun Rodriguez(Director)inMichael Doherty(Director)
Co-investorsFifty YearsGarage CapitalJude GomilaP101 VenturesStrange VenturesY Combinator+3 more
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical DevicesBoston, US
Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD
Co-investorsAtlas VentureNewpath Partners5AM VenturesARCH Venture PartnersDCVC (Data Collective)F-Prime Capital+11 more
Nest Genomics develops genomics solutions to integrate genetic testing into routine patient care.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSaaSNew York City, US
Moran Snir(Founder)inGuy Snir(Founder/COO)in
Co-investorsY CombinatorB Capital GroupB4 CapitalLionBirdMaven VenturesSamsung Next+3 more
.jpeg){kind=logo}
Nomic offers an end-to-end protein profiling service built on its nELISA technology, quantifying up to 1000 informative proteins with absolute quantification for research studies.
BiotechDeep TechHealthtechMedical DevicesMontreal, CA
Milad Dagher(Founder)inJeff Munzar(Founder)in
Co-investorsAmplitude Venture CapitalAvant BioFirst Star VenturesFront Row VenturesRaptor GroupY Combinator+3 more
Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US
Sri Kosuri(Co-founder)inRamsey Homsany(Founder)in
Co-investorsAndreessen Horowitz+ND Capital8VCCarbon SiliconCatalio Capital Management, LPExplorer Investments+8 more
ONI develops the Nanoimager, an automated super-resolution imaging system.
BiotechDeep TechHardwareMedical DevicesOxford, GB
Co-investorsARCH Venture PartnersArtis VenturesFuture Planet CapitalOxford Technology ManagementVertical Venture PartnersAxon Ventures+5 more
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitzARCH Venture PartnersiGlobe PartnersAgent CapitalAlexandriaInvus+2 more
Precision Digital Health captures real-time patient data to enable therapeutic differentiation and support value-based care in clinical research and healthcare delivery.
AI & Machine LearningData & InfrastructureDigital HealthHealthtechSaaSIrvine, US
Jonathan Peters Badgett(Executive Officer)Connie Ellen Pearcy(Executive Officer, Director)
BoardHugh Roome(Director)Patrick Phillips(Director)Thomas Wells(Director)
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Co-investorsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)Luma GroupSanofi VenturesAbingworth+11 more
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Executive Officer, Director, Promoter)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)
Co-investors8VCARCH Venture PartnersFrazier Life SciencesGV (Google Ventures)JDRF T1D FundLAV+6 more
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechHealthtechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in
BoardKristina Burow(Director)inAli Satvat(Director)David Schenkein(Director)in
Co-investorsAisling CapitalARCH Venture PartnersGV (Google Ventures)OrbiMedFidelity InvestmentsRock Springs Capital+1 more
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.
BiotechDeep TechHealthtechLongevityChicago, US
Rand Sutherland(Director)inJames Sullivan(Executive Officer, Director)inJim Sullivan(CEO)inKevin Hunt(CSO)in
BoardJonathan Silverstein(Director)inBernard Davitian(Director)
Co-investorsAvoro Capital AdvisorsOrbiMedOUP (Osage University Partners)Pontifax Venture CapitalAvoro VenturesOmega Funds+1 more
Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.
AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande
Maran Vedamanikam(CEO and Manager)
Co-investorsSamsung NextAndreessen HorowitzWndrCoAlexandriaBiotechnology Value FundFonds de solidarité FTQ+5 more
Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery.
AI & Machine LearningBiotechDeep TechHealthtechWaltham, US
Judith Lieberman(Co-Founder)Daniel Koerwer(Executive Officer)inMichael Crackower(Executive Officer)inZachary McNealy(Executive Officer)Marcelo Bigal, M.D., Ph.D.(President and Chief Executive Officer)
BoardJosh Resnick(Director)in
Co-investorsAndreessen HorowitzGV (Google Ventures)RA CapitalSoftBank Vision FundVersant VenturesBiotechnology Value Fund+2 more
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Executive Officer, Director)inAndrew Bellinger(Executive Officer)
BoardJohn Evans(Director)Anthony Philippakis(Director)inKrishna Yeshwant(Director)in
Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalvenBio PartnersForesite Capital+3 more
Co-investorsLifeforce CapitalCanaan Partners
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsCardinal PartnersNextech InvestSoftBank Vision FundAlexandria+4 more
BiotechSan Francisco, US
Kaz Ohno(Executive Officer)James Lim(Executive Officer)Brian S. Feth(Executive Officer, Director)
BoardSaeid Akhtari(Director)
Co-investorsDynamk CapitalFormic VenturesViking Global Investors
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Cedilla Therapeutics, Inc.PAIGE.AI, Inc.Vitruvian NetworksAmplifyBioLyra TechnologiesMagenta TherapeuticsPYA AnalyticsSexton BiotechnologiesStandard BioTools
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 15
8 IPOs · 7 acquisitions · showing 10AbsciNASDAQ: ABSICentury Therapeutics, Inc.NASDAQ: IPSC4D Molecular TherapeuticsNASDAQ: FDMT908 DevicesNASDAQ: MASSContineum TherapeuticsNASDAQ: CTNMMaze TherapeuticsNASDAQ: MAZENeurogeneNASDAQ: NGNEPrime MedicineNASDAQ: PRMECelsius Therapeuticsacq. by AbbVieVividion Therapeuticsacq. by Bayer
Portfolio news
latest coverage across their companies23andme · en.wikipedia.org · Sep 22, 2026
Neurogene · stocktitan.net · Jun 30, 2026
Leyden Labs · techfundingnews.com · Jun 25, 2026
Absci · stocktitan.net · Jun 24, 2026
City Therapeutics · finsmes.com · Jun 9, 2026
Beacon · finsmes.com · Apr 6, 2026
Asimov · techcrunch.com · Mar 26, 2026
Apella Technology · finsmes.com · Jan 9, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Absci | 6.8% | $16.00 | Jul 2021 | $98.5M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Casdin Capital made?
- Casdin Capital has 68 tracked investments, 15 of which have exited, including 10 dated in the last 24 months.
- What stage does Casdin Capital invest at?
- Casdin Capital invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Casdin Capital focus on?
- Casdin Capital focuses on AI & Machine Learning, Biotech, Deep Tech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Casdin Capital located?
- Casdin Capital is headquartered in New York, US.
- Does Casdin Capital lead rounds?
- Casdin Capital typically participates in rounds rather than leading them.
- Who does Casdin Capital co-invest with?
- Casdin Capital most often shares deals with Breyer Capital, Greylock Partners, IVP (Institutional Venture Partners), among 12 tracked co-investors.
Media · Podcasts & interviews
featuring the teamEli Casdin – Casdin Capital (Manager Meetings, EP.02)
Capital Allocators with Ted Seides · Eli Casdin
The full interview with Casdin Capital's Eli Casdin
Eli Casdin · cnbc.com
Co-investors · 10
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
S32 is a venture capital firm investing at the frontiers of technology, backing exceptional founders with conviction-based investing led by experienced partners.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
Bluebird Ventures is an early-stage venture firm focused on life sciences companies, founded and led by Jeffrey Bird.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Firms observed investing alongside Casdin Capital, from public investor directories. Shared companies are the overlap with Casdin Capital's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
ARTIS Ventures is a venture capital firm investing in breakthrough companies at the convergence of technology and biology, with a focus on healthcare and life sciences ('TechBio'). It backs founders across biotech, therapeutics, digital health, and frontier technologies.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It backs transformative entrepreneurs building industry-defining technologies with global scale potential.